SAB Biotherapeutics (SABS)
NASDAQ:SABS
Want to see SABS full AI Analyst Report?
Top Page
SAB Biotherapeutics
(NASDAQ:SABS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.00
▲(3.90% Upside)
Action:ReiteratedDate:04/23/26
The score is held down primarily by weak financial performance (revenue collapse, ongoing operating losses, and persistent cash burn). Technicals and valuation are more neutral-to-supportive (price modestly above key moving averages and a low P/E), while corporate updates are net positive due to encouraging early clinical signals and added funding—tempered by shareholder dilution risk.
Positive Factors
Proprietary Tc Bovine platform
The Tc Bovine platform is a durable technological moat: it enables production of fully human polyclonal antibodies that are hard to replicate, supports multiple indications, and underpins a diversified pipeline and partner interest, sustaining long-term R&D optionality and commercial potential.
Negative Factors
Revenue collapse
The drop to zero reported revenue by 2025 indicates the company currently has no product-derived cash generation. Sustained revenue absence plus multi-year operating losses means long-term viability depends on successful trials or partnerships rather than existing commercial strength.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Tc Bovine platform
The Tc Bovine platform is a durable technological moat: it enables production of fully human polyclonal antibodies that are hard to replicate, supports multiple indications, and underpins a diversified pipeline and partner interest, sustaining long-term R&D optionality and commercial potential.
Read all positive factors
SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$190.56M
Dividend YieldN/A
Average Volume (3M)398.22K
Price to Earnings (P/E)5.4
Beta (1Y)0.81
Revenue Growth-100.00%
EPS Growth67.23%
CountryUS
Employees63
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.27
Shares Outstanding50,951,040
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.18
Enterprise Value/Ebitda1.73
Forecast
1Y Price Target
$11.67Price Target Upside203.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
SAB Biotherapeutics Business Overview & Revenue Model
Company Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine her...
How the Company Makes Money
null...
SAB Biotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 1.32M | 2.24M | 23.90M | 60.88M |
| Gross Profit | -3.08M | -3.47M | -1.51M | 20.61M | 59.22M |
| EBITDA | 16.60M | -28.99M | -38.13M | -15.12M | -15.20M |
| Net Income | 13.27M | -34.11M | -42.19M | -18.74M | -17.14M |
Balance Sheet | |||||
| Total Assets | 172.81M | 44.20M | 83.94M | 50.90M | 81.14M |
| Cash, Cash Equivalents and Short-Term Investments | 96.59M | 20.76M | 56.57M | 15.05M | 33.21M |
| Total Debt | 5.95M | 4.67M | 5.91M | 5.93M | 8.52M |
| Total Liabilities | 21.32M | 18.23M | 26.64M | 19.85M | 42.59M |
| Stockholders Equity | 151.49M | 25.97M | 57.30M | 31.06M | 38.55M |
Cash Flow | |||||
| Free Cash Flow | -45.71M | -34.63M | -25.32M | -25.63M | -8.96M |
| Operating Cash Flow | -44.78M | -34.29M | -25.12M | -23.46M | 1.99M |
| Investing Cash Flow | -121.71M | -11.96M | -152.70K | -2.09M | -10.94M |
| Financing Cash Flow | 168.30M | -1.17M | 66.77M | 1.05M | 35.89M |
SAB Biotherapeutics Technical Analysis
Neutral
3.85
Price Trends
3.93
Negative
3.93
Negative
3.21
Positive
Market Momentum
-0.01
Negative
48.51
Neutral
67.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Neutral. The current price of 3.85 is above the 20-day moving average (MA) of 3.85, below the 50-day MA of 3.93, and above the 200-day MA of 3.21, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.51 is Neutral, neither overbought nor oversold. The STOCH value of 67.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SABS.
SAB Biotherapeutics Risk Analysis
SAB Biotherapeutics disclosed 80 risk factors in its most recent earnings report. SAB Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SAB Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $47.50M | -1.24 | -16.25% | ― | 34.91% | 84.30% | |
54 Neutral | $32.79M | -0.72 | -152.90% | ― | ― | 8.29% | |
52 Neutral | $190.56M | 5.44 | -21.16% | ― | -100.00% | 67.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $35.70M | -0.71 | -83.59% | ― | ― | 19.36% | |
45 Neutral | $28.41M | -0.97 | -84.39% | ― | -83.00% | 20.34% |
* Healthcare Sector Average
SABS
SAB Biotherapeutics
3.47
1.77
104.12%
LSTA
Lisata Therapeutics
3.13
0.72
29.88%
NXTC
NextCure
9.36
3.96
73.33%
SNSE
Sensei Biotherapeutics
26.96
18.57
221.26%
RLYB
Rallybio
9.41
6.85
267.00%
SAB Biotherapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results
Positive
Apr 22, 2026
On April 22, 2026, SAB BIO presented new clinical and mechanistic data from its Phase 1 HUMAN trial of SAB-142 in adults with established Stage 3 type 1 diabetes at the Immunology of Diabetes Society Congress in Brisbane. All four patients treated...
Business Operations and StrategyPrivate Placements and Financing
SAB Biotherapeutics Launches Major Equity Financing Offering
Positive
Mar 19, 2026
On March 17, 2026, SAB Biotherapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 additional shares, all sold by the company at ...
Business Operations and StrategyProduct-Related Announcements
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data
Positive
Mar 10, 2026
On March 10, 2026, SAB Biotherapeutics, Inc. reported additional Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established autoimmune type 1 diabetes. The company simultaneously made a detailed data pres...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.